A Phase II Trial Evaluating Cisplatin (NSC#119875) and Gemcitabine (NSC#613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advances Squamous Cell Carcinoma of the Vulva

A Phase II Trial Evaluating Cisplatin (NSC#119875) and Gemcitabine (NSC#613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advances Squamous Cell Carcinoma of the Vulva
Recruiting
18 years - 100 years
Female
Phase N/A
13 participants needed
1 Location

Brief description of study

This phase II trial studies how well giving radiation therapy together with gemcitabine hydrochloride and cisplatin work in treating patients with locally advanced squamous cell carcinoma of the vulva.

Detailed description of study

This phase II trial studies how well giving radiation therapy together with gemcitabine hydrochloride and cisplatin work in treating patients with locally advanced squamous cell carcinoma of the vulva.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Squamous Cell Carcinoma of the Vulva,Squamous Cell Carcinoma,Squamous Cell,Carcinoma,Cancer,Vulva Cancer,Oncology
  • Age: 18 years - 100 years
  • Gender: Female

Inclusion Criteria
Patients with locally advanced, previously untreated squamous cell carcinoma of the vulva
Patients with T2 or T3 primary tumors (N0-3, M0) not amenable to surgical resection by standard radical vulvectomy
Absolute neutrophil count (ANC) >= 1,500/mcl
Platelets >= 100,000/mcl
Creatinine =
Exclusion Criteria
Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy
Patients with a history of other invasive malignancies

Updated on 04 Aug 2024. Study ID: 1302010703

Pre-Screener

Check your eligibility-Test
Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study. If you have the common symptoms, you may be eligible to take part in the study.

Preview complete

The prescreener preview is complete. You may now close the preview.

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team